Literature DB >> 11935268

Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis.

Fabián Bernal1, Francesc Graus, Alex Pifarré, Albert Saiz, Baya Benyahia, Teresa Ribalta.   

Abstract

The precise immune mechanisms of neuronal death in anti-Hu-associated paraneoplastic encephalomyelitis (PEM) are unclear. We performed an immunohistochemical study on postmortem brain tissue from 11 patients with anti-Hu-associated PEM to further characterize the immune reaction and to ascertain possible mechanisms of neuronal death. To analyze inflammatory infiltrates, antibodies against lymphocyte subpopulations (CD3, CD20, CD4, CD8), macrophage and activated microglia (CD68), major histocompatibility complex (MHC) classes I and II (HLA-ABC and HLA-DR), and the intercellular adhesion molecules (ICAM) -1 and -3 were used. Cell death mechanisms were defined using antibodies against the cytotoxic protein TIA-1, the C9neo component of complement, the Fas receptor (CD95) and its ligand, the apoptosis effector activated caspase-3, and the apoptosis inhibitor Bcl-2. A great number of T cells expressing the cytotoxic protein TIA-1 was observed, mainly in clusters around neurons. ICAM-1 immunoreactivity was increased in the neuropil and reactive astrocytes in areas of inflammation within the central nervous system and in satellite cells of pathological dorsal root ganglia surrounding apparently normal sensory neurons. By contrast, Fas, FasL, C9neo, and activated caspase-3 immunoreactivities were negative in pathological areas. Bcl-2 immunoreactivity was found in satellite cells, but not in sensory neurons of normal and pathological dorsal root ganglia. Our data point out to an induction of a cytotoxic, non-apoptotic, neuronal death in anti-Hu-associated PEM. The increased ICAM-1 immunoreactivity may favor the infiltration of lymphocytes in the pathological areas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11935268     DOI: 10.1007/s00401-001-0498-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  49 in total

1.  Progress in the management of paraneoplastic neurological disorders.

Authors:  Hamid Sadeghian; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

2.  Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies.

Authors:  Adriaan H C de Jongste; Marieke T de Graaf; Emanuela Martinuzzi; Patricia D M van den Broek; Jaco Kraan; Cor H J Lamers; Roberto Mallone; Jan W Gratama; Peter A E Sillevis Smitt
Journal:  Neuro Oncol       Date:  2012-05-15       Impact factor: 12.300

3.  Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders.

Authors:  Josep Dalmau; Luis Bataller
Journal:  Hematol Oncol Clin North Am       Date:  2006-12       Impact factor: 3.722

Review 4.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

5.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

Review 6.  Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

Authors:  Josep Dalmau; Christian Geis; Francesc Graus
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 7.  Autoimmune encephalitis update.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Neuro Oncol       Date:  2014-03-16       Impact factor: 12.300

8.  Serial MRI of limbic encephalitis.

Authors:  Horst Urbach; Bettina M Soeder; Monika Jeub; Thomas Klockgether; Bernhard Meyer; Christian G Bien
Journal:  Neuroradiology       Date:  2006-04-04       Impact factor: 2.804

Review 9.  Neurologic paraneoplastic syndromes.

Authors:  Edward J Dropcho
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

10.  A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

Authors:  Adriaan H de Jongste; Teun van Gelder; Jacoline E Bromberg; Marieke T de Graaf; Jan W Gratama; Marco W Schreurs; Herbert Hooijkaas; Peter A Sillevis Smitt
Journal:  Neuro Oncol       Date:  2014-07-03       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.